Cancer Immunology, Immunotherapy

, Volume 57, Issue 10, pp 1471–1481

Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis

  • Lisa M. Thornton
  • Barbara L. Andersen
  • William E. CarsonIII
Original Article

Abstract

Background

A period of tumor growth precedes the clinical detection of breast cancer recurrence. We explore immune, endocrine, and behavioral parameters during this period.

Methods

We conducted a phase III clinical trial in which women with surgically treated stage II/III breast cancer (N = 227) were randomized to receive a psychological intervention or assessment-only and then regularly assessed for 10 years. Patients who recurred (R, = 48) were matched with patients remaining disease-free (DF, = 48) on demographic and prognostic characteristics, treatment, and duration of disease-free follow-up. Data at three assessment points, occurring, on average, 17, 11, and 4 months before the recurrence was detected clinically, with equivalent time points for the disease-free group, were examined. Mixed-effects models tested for group differences in immune cell counts and function as well as endocrine and behavioral parameters.

Results

In the 17 months prior to recurrence detection, patients exhibited higher white blood cell count, neutrophil, lymphocyte, and natural killer cell counts, relative to DF patients. R patients also showed higher cortisol, worse physical functioning, fatigue, and quality of life. Follow-up analyses showed patients with local recurrences to differ from those with distant recurrence, with the former exhibiting elevated natural killer cell cytotoxicity, lymphocyte proliferative response, fatigue, pain, and emotional distress (depression, anxiety), and the latter exhibiting higher neutrophil, lymphocyte, and natural killer cell counts.

Conclusion

Patients who would recur showed reliable biobehavioral alterations more than a year prior to their diagnosis. This novel observation may contribute to our understanding of the disease relapse processes.

Keywords

Breast neoplasms Neoplasm metastasis Leukocytes Granulocytes Fatigue Inflammation 

References

  1. 1.
    SPSS 14.0 for Windows. Release 14.0.0. SPSS, Inc, ChicagoGoogle Scholar
  2. 2.
    American Joint Committee on Cancer (1997) AJCC cancer staging manual. Lippincott-Raven, PhiladelphiaGoogle Scholar
  3. 3.
    American Joint Committee on Cancer (2002) AJCC cancer staging manual. In: Greene FL (ed). Springer, New YorkGoogle Scholar
  4. 4.
    Andersen BL, Farrar WB, Golden-Kreutz DM et al (2007) Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun 7:953–961CrossRefGoogle Scholar
  5. 5.
    Andersen BL, Farrar WB, Golden-Kreutz DM et al (2004) Psychological, behavioral, and immune changes following a psychosocial intervention: a clinical trial. J Clin Oncol 17(1):3570–3580CrossRefGoogle Scholar
  6. 6.
    Anisman H, Hayley S, Turrin N et al (2002) Cytokines as a stressor: implications for depressive illness. Int J Neuropsychopharmacol 5(4):357–373PubMedCrossRefGoogle Scholar
  7. 7.
    Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRefGoogle Scholar
  8. 8.
    Bryant J, Day R, Whiteside TL et al (1992) Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods 146(1):91–103PubMedCrossRefGoogle Scholar
  9. 9.
    Colozza M, Azambuja E, Cardoso F et al (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16(11):1723–1739PubMedCrossRefGoogle Scholar
  10. 10.
    Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867PubMedCrossRefGoogle Scholar
  11. 11.
    Demicheli R, Retsky MW, Swartzendruber DE et al (1997) Proposal for a new model of breast cancer metastatic development. Ann Oncol 8(11):1075–1080PubMedCrossRefGoogle Scholar
  12. 12.
    Demicheli R, Terenziani M, Bonadonna G (1998) Estimate of tumor growth time for breast cancer local recurrences: rapid growth after wake-up? Breast Cancer Res Treat 51(2):133–137PubMedCrossRefGoogle Scholar
  13. 13.
    di Carlo E, Iezzi M, Pannellini T et al (2001) Neutrophils in anti-cancer immunological strategies: old players in new games. J Hematother Stem Cell Res 10(6):739-748PubMedCrossRefGoogle Scholar
  14. 14.
    Furihata M, Sonobe H, Ohtsuki Y et al (1999) An immunohistochemical study on a case of granulocyte-colony stimulating factor-producing gall-bladder carcinoma. Pathol Int 49(11):1010–1013PubMedCrossRefGoogle Scholar
  15. 15.
    Imai K, Matsuyama S, Miyake S et al (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356(Nov 25):1795–1799PubMedCrossRefGoogle Scholar
  16. 16.
    Inoue M, Minami M, Fujii Y et al (1997) Granulocyte colony-stimulating factor and interleukin-6-producing lung cancer cell line, LCAM. J Surg Oncol 64(4):347–350PubMedCrossRefGoogle Scholar
  17. 17.
    Jakobisiak M, Lasek W, Golab J (2003) Natural mechanisms protecting against cancer. Immunol Lett 90(2–3):103–122PubMedCrossRefGoogle Scholar
  18. 18.
    Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 199–205Google Scholar
  19. 19.
    Kee JL (2005) Laboratory and diagnostic tests. Pearson Education, Upper Saddle RiverGoogle Scholar
  20. 20.
    Levy SM, Herberman RB, Lippman M et al (1991) Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav Med 17:67–75PubMedCrossRefGoogle Scholar
  21. 21.
    Levy SM, Wise BD (1987) Psychosocial risk factors, natural immunity, and cancer progression: Implications for intervention. Health Psychol 6(3):229–43Google Scholar
  22. 22.
    McNair DM, Lorr M, Droppleman LF (1971) EITS manual for the profile of mood states. Educational and Industrial Testing Service, San DiegoGoogle Scholar
  23. 23.
    Moinpour CM, Feigl P, Metch B et al (1989) Quality of life end points in cancer clinical trials: Review and recommendations. J Natl Cancer Inst 81(7):485–495PubMedCrossRefGoogle Scholar
  24. 24.
    Morrow GR, Andrews PL, Hickok JT et al (2002) Fatigue associated with cancer and its treatment. Support Care Cancer 10:389–398PubMedCrossRefGoogle Scholar
  25. 25.
    Nagtegaal ID, Marijnen CA, Kranenbarg EK et al (2001) Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect—a histopathological and immunohistochemical study. BMC Cancer 1:7PubMedCrossRefGoogle Scholar
  26. 26.
    Norton L (1988) A Gompertzian model of human breast cancer growth. Cancer Res 49(22):6443–6444Google Scholar
  27. 27.
    Ownby HE, Roi LD, Isenberg RR et al (1983) Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 52(1):126–130PubMedCrossRefGoogle Scholar
  28. 28.
    Papatestas AE, Lesnick GJ, Genkins G et al (1976) The prognostic significance of peripheral lymphocyte counts in patients with breast carcinoma. Cancer 37(1):164–168PubMedCrossRefGoogle Scholar
  29. 29.
    Rook GA (1999) Glucocorticoids and immune function. Baillieres Clin Endocrinol Metab 13(4):567–581CrossRefGoogle Scholar
  30. 30.
    Rotstein S, Blomgren H, Petrini B et al (1985) Blood lymphocyte counts with subset analysis in operable breast cancer. Relation to the extent of tumor disease and prognosis. Cancer 56(6):1413–1419PubMedCrossRefGoogle Scholar
  31. 31.
    Ruka W, Rutkowski P, Kaminska J et al (2001) Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol 12(10):1423–1432PubMedCrossRefGoogle Scholar
  32. 32.
    Thornton LM, Andersen BL, Crespin TR et al (2007) Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav Immun 21(2):185–194PubMedCrossRefGoogle Scholar
  33. 33.
    Walsh SR, Cook EJ, Goulder F et al (2005) Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91(3):181–184PubMedCrossRefGoogle Scholar
  34. 34.
    Ware JE, Snow KK, Kosinski M (2000) SF-36 health survey: manual and interpretation guide. QualityMetric Incorporated, LincolnGoogle Scholar
  35. 35.
    Whitehead RH, Thatcher J, Teasdale C et al (1976) T and B lymphocytes in breast cancer stage relationship and abrogation of T-lymphocyte depression by enzyme treatment in vitro. Lancet 14(1):330–33CrossRefGoogle Scholar
  36. 36.
    Wiltschke C, Krainer M, Budinsky AC et al (1995) Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study. Br J Cancer 71:1292–1296PubMedGoogle Scholar
  37. 37.
    Yamasaki S, Kan N, Harada T et al (1993) Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy. Breast Cancer Res Treat 26(1):55–65PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Lisa M. Thornton
    • 1
  • Barbara L. Andersen
    • 1
    • 2
  • William E. CarsonIII
    • 2
  1. 1.Department of PsychologyOhio State UniversityColumbusUSA
  2. 2.Comprehensive Cancer CenterOhio State UniversityColumbusUSA

Personalised recommendations